glp 1 agonists uses Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 GLP-1 Agonists Examples: Which One

A., Semaglutide for the Treatment of Obesity, Trends in Cardiovascular Medicine 33 (2023): 159166

Clinical studies A total of 22 completed clinical studies were identified (Table 1 and Extended Data Tables 1 and 2), with another 8 clinical trials still ongoing (Supplementary Section 3)

Clinical evidence suggests minimal semaglutide transfer into breast milk due to its large molecular size (4,113 daltons), but this decision requires explicit discussion with your OB/GYN and pediatrician

AMPK antagonizes mammalian target of rapamycin (mTOR) activity, and its downstream effector, p27, inhibits cyclin-dependent kinase 2 (CDK2), thereby blocking the G1/S transition in the cell cycle, halting cell division, and subsequently inhibiting cellular proliferation [57]

This means your doctor may recommend a medicine for a condition it hasnt been approved by the U.S